联合疫苗监管科学与创新审批路径会议报告
联合疫苗可减少接种次数,但研发复杂、成本高且管线稀少,部分源于监管对临床终点及精度的要求。世界卫生组织与PATH于2025年3月召集十二国监管机构、研发方及公共卫生官员,探讨多种免疫标志物、受控人类感染模型及临床终点替代策略,监管方欢迎科学合理的创新提议并以整体获益-风险为核心。
要点
- 联合疫苗可减少接种次数,对扩大免疫规划覆盖至关重要。
- 监管对主要临床终点及精度的要求推高样本量、成本与研究时长。
- 监管方接受科学合理的创新效力论证,以整体获益-风险为审批核心。
核心结论
- 监管机构欢迎科学合理的创新效力论证方案,并同意联合疫苗审批应以整体获益-风险为主要关注点。
研究设计与样本
- 世界卫生组织与PATH于2025年3月协调召开为期一天的会议,汇集来自十二个国家的现任及前任国家监管机构人员、疫苗研发方、资助与采购机构代表以及公共卫生与政策官员。
主要发现
- 与会者讨论了多种免疫标志物和受控人类感染模型(CHIM)如何有助于证明疫苗效力。
- 与会者考虑了当联合疫苗各组分针对引起同一疾病综合征的病原体、但无法对每个组分的贡献进行病原学判定时,依赖临床终点的可能性。
- 目前联合疫苗管线中的组合较少,部分原因是其研发相比单独制剂固有地更复杂且成本更高。
- 这种复杂性部分源于围绕联合疫苗临床研究项目的监管要求,尤其是主要临床终点及围绕这些终点所需的精确度,因为这些最终决定研究的样本量、成本和持续时间。
临床怎么用
- 在联合疫苗效力论证中可考虑采用多种免疫标志物和受控人类感染模型(CHIM)作为支持性证据。
- 当各组分针对同一疾病综合征且无法病原学区分贡献时,可与监管方沟通依赖临床终点的可行性。
- 与监管机构沟通时以联合疫苗整体获益-风险为核心框架提出科学合理的创新方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combination vaccine formulations contain distinct components targeting multiple strains of a single pathogen or multiple pathogens. By minimizing the number of separate vaccine administrations required, combination vaccines have been critical in allowing the broad expansion of the number and range of diseases that can now be prevented by immunization. Recent advances in vaccine development and our understanding of the immune system now make it possible to envision how new combination vaccines could play a major role in helping immunization programs address a much wider range of emerging or still problematic pathogens. However, few combinations are currently in the pipeline, in part due to their inherently increased complexity and cost of development compared to standalone formulations. This complexity, in turn, is partly driven by the regulatory requirements surrounding the clinical study program for the combination vaccine, especially the primary clinical endpoints and the required degree of precision around those endpoints, as these ultimately determine the sample size, cost, and duration of the study. As part of a larger effort to facilitate combination vaccine development, vaccine experts at the World Health Organization and PATH coordinated a one-day meeting in March 2025 gathering current and former national regulatory agency staff from a dozen countries, together with vaccine developers, representatives from funding and procurement agencies, and public health and policy officials. The convened participants held spirited discussions on how multiple immune markers and controlled human infection models (CHIM) might contribute to the demonstration of vaccine efficacy. In addition, participants considered the possibility of relying on clinical endpoints when the vaccine components are directed against pathogens causing the same disease syndrome but etiological determination of each component's contribution is not feasible. Regulators welcomed scientifically sound, creative proposals for demonstration of efficacy, and agreed that the benefit-risk of the combination vaccine as a whole should be the primary focus.
引用
- Hausdorff WP, Cavaleri M, Gruber MF, et al. Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines. Vaccine. 2026. PMID: 41579754. doi:10.1016/j.vaccine.2026.128257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。